Lifileucel has demonstrated improved response rates in patients with advanced or unresectable melanoma who have progressed following treatment with immune checkpoint inhibitors and, when applicable, BRAF/MEK inhibitors [34]. This evidence concerns the gene MAP2K7 and melanoma.